Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond L H Lam

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 14, 2004
Comparison of methods based on diversity and similarity for molecule selection and the analysis of drug discovery dataRaymond L H Lam, William J Welch
Current Opinion in Drug Discovery & Development|June 13, 2002
Initial compound selection for sequential screeningS Stanley Young, Raymond L H Lam, William J Welch
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 25, 2018
Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical TrialsAnnaswamy Raji, Jianmin Long, Raymond L H Lam, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 28, 2020
Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal InsufficiencyAnnaswamy Raji, Zhi Jin Xu, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|July 19, 2018
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R studyRussell Scott, Jerry Morgan, Zachary Zimmer, et al.
Journal of Hepatology|June 24, 2023
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseManuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, et al.
Diabetes, Obesity & Metabolism|May 17, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trialPhilip D Home, Raymond L H Lam, Wendy L Carofano, et al.
Diabetes, Obesity & Metabolism|January 5, 2019
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M studyJuan P Frias, Zachary Zimmer, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|May 16, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trialPriscilla A Hollander, Wendy L Carofano, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|May 14, 2004
Comparison of methods based on diversity and similarity for molecule selection and the analysis of drug discovery dataRaymond L H Lam, William J Welch
Current Opinion in Drug Discovery & Development|June 13, 2002
Initial compound selection for sequential screeningS Stanley Young, Raymond L H Lam, William J Welch
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 25, 2018
Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical TrialsAnnaswamy Raji, Jianmin Long, Raymond L H Lam, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 28, 2020
Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal InsufficiencyAnnaswamy Raji, Zhi Jin Xu, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|July 19, 2018
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R studyRussell Scott, Jerry Morgan, Zachary Zimmer, et al.
Journal of Hepatology|June 24, 2023
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseManuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, et al.
Diabetes, Obesity & Metabolism|May 17, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trialPhilip D Home, Raymond L H Lam, Wendy L Carofano, et al.
Diabetes, Obesity & Metabolism|January 5, 2019
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M studyJuan P Frias, Zachary Zimmer, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|May 16, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trialPriscilla A Hollander, Wendy L Carofano, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyRonan Roussel, Santiago Duran-García, Yilong Zhang, et al.
Pageof 2